Robert Randolph Edwards

Robert Randolph Edwards

Auto-generated profile, based on publicly available information

Robert Randolph Edwards

Department of Anesthesiology, Perioperative, and Pain Medicine, Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
PQPhillip J Quartana
Phillip J Quartana
CCClaudia M Campbell
Claudia M Campbell
RERobert R Edwards
Robert R Edwards
Pain catastrophizing is conceptualized as a negative cognitive–affective response to anticipated or actual pain and has been associated with a number of important pain-related outcomes. In the pres...

1 September 2016 in The Journal of Pain
Verified
Journal Article
Closed access
RERobert R. Edwards
Robert R. Edwards
RDRobert H. Dworkin
Robert H. Dworkin
MSMark D. Sullivan
Mark D. Sullivan
DTDennis C. Turk
Dennis C. Turk
AWAjay D. Wasan
Ajay D. Wasan

1 February 2011 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
RERobert R. Edwards
Robert R. Edwards
CCChristine Cahalan
Christine Cahalan
GMGeorge Mensing
George Mensing
MSMichael Smith
Michael Smith
JHJennifer A. Haythornthwaite
Jennifer A. Haythornthwaite

18 May 2012 in Pain Management
Verified
Journal Article
Closed access
CCClaudia M Campbell
Claudia M Campbell
RERobert R Edwards
Robert R Edwards
SUMMARY Considerable evidence demonstrates substantial ethnic disparities in the prevalence, treatment, progression and outcomes of pain-related conditions. Elucidating the mechanisms underlying th...

5 May 2016 in Pain
Verified
Journal Article
Closed access
RERobert R. Edwards
Robert R. Edwards
RDRobert H. Dworkin
Robert H. Dworkin
DTDennis C. Turk
Dennis C. Turk
MAMartin S. Angst
Martin S. Angst
RDRaymond Dionne
Raymond Dionne
DYDavid Yarnitsky
David Yarnitsky
There is tremendous interpatient variability in the response to analgesic therapy (even for efficacious treatments), which can be the source of great frustration in clinical practice. This has led to calls for “precision medicine” or personalized pain therapeutics (ie, empirically based algorithms that determine the optimal treatments, or treatment combinations, for individual patients) that would presumably improve both the clinical care of patients with pain and the success rates for putative analgesic drugs in phase 2 and 3 clinical trials. However, before implementing this approach, the characteristics of individual patients or subgroups of patients that increase or decrease the response to a specific treatment need to be identified. The challenge is to identify the measurable phenotypic characteristics of patients that are most predictive of individual variation in analgesic treatment outcomes, and the measurement tools that are best suited to evaluate these characteristics. In this article, we present evidence on the most promising of these phenotypic characteristics for use in future research, including psychosocial factors, symptom characteristics, sleep patterns, responses to noxious stimulation, endogenous pain-modulatory processes, and response to pharmacologic challenge. We provide evidence-based recommendations for core phenotyping domains and recommend measures of each domain.

1 January 2019 in Brain, Behavior, and Immunity
Verified
Journal Article
Open access
DADaniel S. Albrecht
Daniel S. Albrecht
AFAnton Forsberg
Anton Forsberg
ASAngelica Sandström
Angelica Sandström
CBCourtney Bergan
Courtney Bergan
DKDiana Kadetoff
Diana Kadetoff
MLMarco L. Loggia
Marco L. Loggia
Fibromyalgia (FM) is a poorly understood chronic condition characterized by widespread musculoskeletal pain, fatigue, and cognitive difficulties. While mounting evidence suggests a role for neuroinflammation, no study has directly provided evidence of brain glial activation in FM. In this study, we conducted a Positron Emission Tomography (PET) study using [11C]PBR28, which binds to the translocator protein (TSPO), a protein upregulated in activated microglia and astrocytes. To enhance statistical power and generalizability, we combined datasets collected independently at two separate institutions (Massachusetts General Hospital [MGH] and Karolinska Institutet [KI]). In an attempt to disentangle the contributions of different glial cell types to FM, a smaller sample was scanned at KI with [11C]-L-deprenyl-D2 PET, thought to primarily reflect astrocytic (but not microglial) signal. Thirty-one FM patients and 27 healthy controls (HC) were examined using [11C]PBR28 PET. 11 FM patients and 11 HC were scanned using [11C]-L-deprenyl-D2 PET. Standardized uptake values normalized by occipital cortex signal (SUVR) and distribution volume (VT) were computed from the [11C]PBR28 data. [11C]-L-deprenyl-D2 was quantified using λ k3. PET imaging metrics were compared across groups, and when differing across groups, against clinical variables. Compared to HC, FM patients demonstrated widespread cortical elevations, and no decreases, in [11C]PBR28 VT and SUVR, most pronounced in the medial and lateral walls of the frontal and parietal lobes. No regions showed significant group differences in [11C]-L-deprenyl-D2 signal, including those demonstrating elevated [11C]PBR28 signal in patients (p's ≥ 0.53, uncorrected). The elevations in [11C]PBR28 VT and SUVR were correlated both spatially (i.e., were observed in overlapping regions) and, in several areas, also in terms of magnitude. In exploratory, uncorrected analyses, higher subjective ratings of fatigue in FM patients were associated with higher [11C]PBR28 SUVR in the anterior and posterior middle cingulate cortices (p's < 0.03). SUVR was not significantly associated with any other clinical variable. Our work provides the first in vivo evidence supporting a role for glial activation in FM pathophysiology. Given that the elevations in [11C]PBR28 signal were not also accompanied by increased [11C]-L-deprenyl-D2 signal, our data suggests that microglia, but not astrocytes, may be driving the TSPO elevation in these regions. Although [11C]-L-deprenyl-D2 signal was not found to be increased in FM patients, larger studies are needed to further assess the role of possible astrocytic contributions in FM. Overall, our data support glial modulation as a potential therapeutic strategy for FM.